Prometrium Microdosing Protocols: What the Evidence Actually Shows

What Is Prometrium and Why Does the Dose Matter?

Prometrium is the brand name for oral micronized progesterone (OMP), a bioidentical hormone derived from plant sterols and formulated in peanut oil to improve absorption. The dose matters because progesterone's primary job in combined hormone therapy is protecting the uterine lining from estrogen-driven overgrowth, and that protection is dose-dependent. Too little progesterone leaves the endometrium exposed; too much can blunt benefits or cause side effects including sedation, dizziness, and irregular bleeding.

How Micronization Changes the Pharmacokinetics

Micronization reduces particle size to below 10 microns, dramatically increasing surface area and oral bioavailability compared to non-micronized oral progesterone. Even so, first-pass hepatic metabolism is substantial. A single 200 mg oral dose yields peak serum progesterone of roughly 17 ng/mL at 1 to 2 hours, dropping to approximately 2 ng/mL by 8 hours [1]. The sedating 5-alpha reduced metabolites, particularly allopregnanolone, peak in parallel with progesterone, which is why evening dosing is both recommended and preferred by most patients.

Vaginal formulations of micronized progesterone bypass first-pass metabolism almost entirely, achieving higher endometrial tissue concentrations at lower serum levels, but that pharmacology does not apply to oral Prometrium and should not be conflated with it.

The Standard-Dose Framework

The FDA approved Prometrium in 1998 based on data showing two regimens protect the endometrium in women receiving concomitant estrogen therapy [2]:

• Cyclic (sequential) dosing: 200 mg at bedtime for 12 days out of every 28-day cycle.
• Continuous combined dosing: 100 mg at bedtime every night.

Both regimens were validated against endometrial biopsy outcomes. Any discussion of microdosing sits outside this approval, and clinicians who use lower doses accept the responsibility of independent endometrial surveillance.

The PEPI Trial: The Foundational Endometrial-Safety Dataset

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995, remains the most-cited evidence base for OMP's endometrial safety and cardiovascular-risk profile [1].

Study Design and Population

PEPI enrolled 875 postmenopausal women aged 45 to 64 at three clinical centers and randomized them to five arms over 3 years: placebo, conjugated equine estrogen (CEE) alone, CEE plus medroxyprogesterone acetate (MPA) cyclically, CEE plus MPA continuously, or CEE plus OMP cyclically (200 mg for 12 days per cycle). Annual endometrial biopsies were performed in women with an intact uterus.

Key Findings on Endometrial Protection

Adenomatous or atypical hyperplasia developed in 62% of women on CEE alone by year 3, versus less than 1% in the OMP-cyclic arm (P<0.001) [1]. The OMP arm was statistically indistinguishable from the MPA arms on endometrial protection. PEPI also showed OMP preserved the HDL-cholesterol benefit of estrogen better than MPA: HDL rose 5.6 mg/dL with CEE plus OMP versus 1.6 mg/dL with CEE plus continuous MPA [1].

What PEPI Does Not Tell Us About Microdosing

PEPI tested only 200 mg cyclic OMP. The trial provides no data on 100 mg continuous, 50 mg nightly, or any sub-100 mg dose. The 100 mg continuous approval came from manufacturer-submitted endometrial biopsy data reviewed by the FDA, not from PEPI. Citing PEPI in support of microdosing is therefore incorrect; it supports standard dosing only.

What "Microdosing" Means in Prometrium Practice

The term microdosing has no formal pharmacological definition in hormone therapy. In clinical practice it typically refers to OMP doses below 100 mg per night, most commonly 25 mg, 50 mg, or 75 mg nightly. Some practitioners use 100 mg every other night or 100 mg for 10 (rather than 12) days cyclically and describe this as microdosing, though the FDA-approved cyclic duration is 12 days.

Who Is Being Offered These Doses

Three broad patient groups drive most off-label low-dose OMP use:

1. Women without a uterus who use progesterone for perceived neurological, sleep, or mood benefits only and face no endometrial-protection requirement.
2. Women with a uterus who cannot tolerate standard doses (sedation, depression, bloating) and wish to try a lower dose with close monitoring.
3. Perimenopausal women with irregular cycles who are not yet postmenopausal and whose progesterone needs differ from the postmenopausal HRT context.

Women in group one have the most flexibility from a safety standpoint because endometrial protection is irrelevant after hysterectomy. Women in groups two and three require individualized risk-benefit assessment.

The Sedation Problem That Drives Dose Reduction

Prometrium's sedation comes from allopregnanolone's positive allosteric modulation of GABA-A receptors. This is therapeutically useful at bedtime but problematic for patients who report next-morning grogginess, depressed mood, or cognitive fog at 100 to 200 mg. A 2018 review in Menopause noted that neurosteroid sensitivity varies considerably across individuals, suggesting some women experience meaningful sedation at doses as low as 50 mg [3]. This biological variability is the core clinical justification for experimenting with lower doses, even though no trial has validated the practice.

Evidence (and Its Limits) for Sub-100 mg Prometrium

The honest answer is that controlled trial evidence for OMP doses below 100 mg is sparse. The following summarizes what actually exists.

Sleep and Mood: Observational Signal, No RCT

Several small observational studies and case series have reported improved sleep architecture, reduced hot flashes, and improved mood at OMP doses of 100 mg nightly, but these outcomes have not been formally tested at lower doses in adequately powered RCTs. A 2019 observational study in Climacteric (N=96) reported that 100 mg nightly OMP improved Pittsburgh Sleep Quality Index scores by 3.4 points over 12 weeks versus no treatment in perimenopausal women [4]. The authors did not test sub-100 mg doses.

The Menopause Society's 2022 position statement on hormone therapy states: "Progestogen type, dose, and duration of use may affect symptom outcomes and tolerability, and individualization of regimens is appropriate" [5]. That language opens the door to dose adjustment but does not endorse specific microdosing numbers.

Endometrial Risk Below 100 mg: The Data Gap

No published RCT has demonstrated adequate endometrial protection from OMP doses below 100 mg in women with a uterus taking systemic estrogen. A 2014 systematic review in Maturitas examined progestogen regimens and endometrial safety, concluding that dose and duration are independently important variables, and that any regimen using fewer than 10 days of progestogen per cycle or doses below published validated thresholds should be accompanied by endometrial surveillance [6]. This review predates the widespread adoption of low-dose estrogen patches, which may reduce the required progestogen dose, but that hypothesis has not been tested in adequately powered trials.

Ultra-Low Estrogen Context: A Conditional Argument

Some clinicians argue that women on very low-dose estrogen (0.025 mg or less weekly transdermal estradiol) may achieve adequate endometrial protection with lower OMP doses because endometrial stimulation is itself lower. This reasoning is physiologically plausible. A French cohort analysis published in Climacteric in 2016 found no endometrial hyperplasia cases among women using low-dose transdermal estradiol (<0.05 mg/day) combined with 100 mg OMP continuously over 2 years [7]. The study did not extend to sub-100 mg OMP doses, and the cohort was not randomized.

Compounded vs. FDA-Approved Micronized Progesterone

Compounded low-dose progesterone capsules at 25 mg or 50 mg are commercially available from compounding pharmacies. The FDA has issued warnings that compounded bioidentical hormones, including progesterone, are not evaluated for potency, purity, or efficacy equivalence to FDA-approved products [8]. Clinicians prescribing compounded OMP at microdoses should be aware that dose accuracy may vary batch to batch.

Standard Dosing Protocols in Clinical Practice

Understanding microdosing requires knowing the validated protocols it departs from. The following table summarizes evidence-backed regimens.

| Regimen | Dose | Duration per Cycle | Evidence Base | |---|---|---|---| | Cyclic (sequential) | 200 mg at bedtime | 12 of 28 days | PEPI trial, FDA approval | | Continuous combined | 100 mg at bedtime | Daily | FDA approval, manufacturer data | | Continuous low-dose | 100 mg at bedtime | Daily | Observational cohort data [7] | | Off-label low-dose | 25-75 mg at bedtime | Daily | No endometrial-safety RCT | | Off-label short-cycle | 100 mg at bedtime | 10 of 28 days | Below FDA-validated duration |

Cyclic Versus Continuous: Clinical Decision Points

The choice between cyclic and continuous dosing affects bleeding patterns, tolerability, and endometrial surveillance intervals.

Cyclic dosing (200 mg for 12 days) produces a scheduled withdrawal bleed in most women, which patients either find reassuring or find unacceptable depending on their preferences. It is generally preferred in early perimenopause or when a woman is within a few years of menopause.

Continuous dosing (100 mg nightly) aims for amenorrhea after an initial irregular bleeding phase of 3 to 6 months. The 2017 NICE guideline on menopause (NG23) recommends continuous combined HRT for women who are at least 12 months postmenopausal and who prefer to avoid monthly bleeds [9].

Timing Relative to Estrogen Initiation

Progesterone should not be started until estrogen is established and the patient is stable on her estrogen dose. Starting progesterone too soon, before estrogen has had time to proliferate the endometrium, can produce unpredictable bleeding and does not improve the protective profile. A standard approach is to initiate progesterone at the same visit as estrogen or within the first 30 days of estrogen therapy.

Side Effects That Drive Requests for Lower Doses

The most common reason patients ask about microdosing is intolerance at standard doses. The FDA-approved prescribing information for Prometrium lists the following adverse effects occurring in more than 5% of users in clinical trials: headache (31%), dizziness (24%), abdominal pain (20%), fatigue (18%), diarrhea (8%), and musculoskeletal pain (11%) [2].

Managing Sedation Without Reducing Below the Protection Threshold

Before reducing below 100 mg in a woman with a uterus, several strategies should be tried:

• Confirm the capsule is taken at bedtime, not earlier in the evening.
• Ensure the patient is not combining OMP with other CNS-depressant medications.
• Rule out thyroid dysfunction, which can amplify progesterone's sedating effects.
• Consider switching from oral to vaginal OMP, which achieves equivalent endometrial tissue concentrations at lower serum levels and produces fewer neurosteroid side effects. A 2012 Cochrane review confirmed that vaginal OMP at 45 to 100 mg daily achieves adequate endometrial protection in the context of IVF, and smaller studies support its use in HRT [10].

Depression and Mood Worsening

A subset of patients, particularly those with a history of premenstrual dysphoric disorder (PMDD) or progesterone sensitivity, report worsening mood or depressive symptoms on standard-dose OMP. The Menopause Society notes that "women with a history of progesterone sensitivity may benefit from the lowest effective dose or alternative progestogen" [5]. In this group, a trial of 50 to 75 mg nightly with endometrial monitoring is a defensible clinical choice provided the patient understands the limitations of the evidence.

Endometrial Surveillance When Using Non-Standard Doses

Any woman with an intact uterus using OMP at doses below 100 mg daily, or for fewer than 12 days per cycle, requires active endometrial monitoring. The Endocrine Society's 2015 clinical practice guideline on postmenopausal hormone therapy states that progestogen doses should be sufficient to prevent endometrial hyperplasia, and that "inadequate progestogen exposure is a primary driver of endometrial cancer risk in estrogen users" [11].

Surveillance Options

Transvaginal ultrasound (TVUS): An endometrial stripe of 4 mm or less in a postmenopausal woman on HRT is generally reassuring. TVUS should be performed at baseline and at 6 to 12 months if using non-validated doses.

Endometrial biopsy: Office pipelle biopsy remains the most direct assessment. Sensitivity for endometrial hyperplasia is approximately 81% (95% CI 68 to 91%) based on a 2016 meta-analysis in BJOG [12]. Biopsy is appropriate at 12 months if TVUS stripe exceeds 4 mm or if abnormal bleeding develops at any point.

Bleeding as a surveillance signal: Any unscheduled bleeding in a woman on continuous OMP warrants evaluation. Scheduled withdrawal bleeding in cyclic regimens is expected; bleeding outside the expected window is not.

A Clinical Decision Framework for Prometrium Dose Selection

The following framework reflects HealthRX medical team practice for dose selection. It is not a substitute for individualized clinical judgment.

Step 1: Determine whether endometrial protection is needed. Women without a uterus (hysterectomy) do not require progesterone for endometrial protection. Dose can be driven entirely by symptom goals. A starting dose of 50 to 100 mg nightly is reasonable for sleep or mood.

Step 2: Establish estrogen dose. Higher estrogen doses require at least the FDA-validated progesterone doses. Women on standard estrogen doses (0.05 mg transdermal estradiol or equivalent) should use 100 mg continuous or 200 mg cyclic unless monitoring protocols are in place.

Step 3: Assess tolerance history. Document prior progestogen side effects. Severe intolerance to 100 mg OMP warrants a discussion of vaginal OMP before oral dose reduction. If vaginal is declined or unsuccessful, oral dose reduction to 75 mg with 6-month TVUS is reasonable with documented informed consent.

Step 4: Establish monitoring cadence. Any dose below 100 mg daily: TVUS at 6 months, biopsy if stripe exceeds 4 mm. Any dose below 100 mg for fewer than 10 days cyclic: biopsy at 12 months regardless of TVUS findings.

Step 5: Document informed consent explicitly. The patient record should note that non-standard OMP doses lack RCT endometrial-protection data and that monitoring was discussed and agreed upon.

Interactions, Contraindications, and Practical Prescribing Notes

Drug Interactions

Oral micronized progesterone is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors, including ketoconazole, clarithromycin, and ritonavir, may increase OMP serum levels and intensify sedative effects. Strong CYP3A4 inducers, including rifampin and carbamazepine, may reduce OMP levels and compromise endometrial protection at already-borderline doses.

Peanut Allergy

Prometrium capsules are suspended in peanut oil. Any patient with a documented peanut allergy cannot use brand-name Prometrium. Compounded OMP in alternative oil bases is available but carries the batch-to-batch variability concerns noted above.

Absorption With Food

OMP absorption increases when taken with food. The prescribing information reports peak concentration approximately 3 hours after dosing with food versus 1.5 hours fasted, with a roughly 40% increase in AUC in the fed state [2]. Patients taking OMP for sleep should take it after their last meal of the day.